News Roche offers $15bn for strategic-level deal with Hansoh A year after signing a first deal with Hansoh worth up to $1.45 billion, Roche has returned for another that could be more than 10 times larger.
News Zealand forges obesity alliance with AI specialist Generate Zealand has added another strand to its programme of weight-loss drug development, linking with AI player Generate on multispecific protein therapies.
News CSL joins forces with Alentis on claudin candidate CSL has licensed rights to a potentially first-in-class anti-claudin-1 antibody developed by Alentis in a deal that could be worth up to $1.55bn.
News Novartis taps China's Abogen for autoimmunity TCE Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.
News Sanofi forges new $8bn pact with Regeneron Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a new deal – including a $1bn upfront payment – that spans four new drugs.
News AZ takes stake in Summit Therapeutics in $2bn deal AstraZeneca has taken a roughly 10% stake in Summit and signed a deal to test CLDN18.2-targeting sone-ve with PD-1xVEGF bispecific ivonescimab.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.